商品编号


AG-40T-0552-C025



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

25 ?g

商品信息


More Information



Product Details



Synonyms

E3 Ubiquitin-protein Ligase Parkin; PARK2; Parkinson Juvenile Disease Protein 2; AR-JP; E3 Ubiquitin Ligase; LPRS2; Parkinson Disease Protein 2; PDJ; PRKN



Product Type

Protein



Properties



Source/Host

Sf21 cells



Sequence

Human Parkin (Accession Nr. O60260). This protein is untagged.



Crossreactivity

Human



MW

~52kDa



Purity

≥90% (SDS-PAGE)



Formulation

Liquid. In 25mM Tris-HCl pH 8.5, 200mM NaCl, 0.03% Brij35, 10% (v/v) Glycerol, 5mM TCEP.



Other Product Data


Use:
As supplied, Parkin has neglig
IBL
e E3 ligase activity as determined by the lack of autoubiquitination in an
in vitro
assay. Parkin ligase activity is greatly enhanced by phosphorylation with PINK1 kinase or by the addition of low concentrations of phosphorylated Ubiquitin. Reaction conditions will need to be optimized for each specific application.



Declaration

Manufactured by Boston Biochem



Shipping and Handling



Shipping

DRY ICE



Short Term Storage

-20°C



Long Term Storage

-80°C



Handling Advice

Aliquot to avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -80°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





The E3 Ubiquitin ligase Parkin (encoded by the PARK2 gene) is an essential part of the cellular machinery that participates in the removal of damaged mitochondria. Mutations in PARK2 are known to cause a form of Parkinson's disease known as autosomal recessive juvenile Parkinson's disease (AR-JP) and the mechanisms by which defective Parkin ligase contributes to the dopaminergic cell death in this disease is an area of intense investigation. Reported substrates for Parkin include BCL2, GPR37, MIRO1, MFN1, MFN2, TOMM20,
USP
30 and many others. Parkin (an RBR-class Ubiquitin ligase) structures have recently been reported by multiple groups and reveal that the ligase is folded upon itself to produce an auto-inhibited state. The auto-inhibition is relieved by interactions with PINK1 kinase (which can phosphorylate both Parkin and Ubiquitin at serine residue number 65) and pS65 phospho-Ubiquitin by mechanisms that are under investigation. In vitro, Parkin may be activated by treatment with recombinant PINK1, or addition of low concentrations of pS65-phosphoubiquitin. Parkin has been reported to generate poly-Ubiquitin chains in K6, K11, K48, and K63 linkages both
in vitro
and
in vivo
.